Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter, IDT Sign Application Development Agreement for NGS Library Prep System

NEW YORK – Beckman Coulter Life Sciences announced on Monday that it has inked an application development agreement with Integrated DNA Technologies for its forthcoming Biomek NGenius next-generation library preparation system.

Financial and other terms of the deal were not disclosed.

The agreement will allow IDT to develop next-generation sequencing applications specifically designed for the instrument that will be available to users via an electronic application library. The system is an automated liquid handler that reduces manual transfers and hands-on time for NGS library construction, Beckman Coulter said in a statement.

Danaher subsidiary Beckman Coulter added that the IDT agreement is the second application development agreement for the instrument, which is expected to launch in the first quarter of 2022.

"Automating our NGS solutions on Beckman Coulter Life Sciences' new Biomek NGenius system is an important step in making high-performance NGS solutions more accessible to a broader array of labs," Mirna Jarosz, IDT's general manager of NGS, said in a statement.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.